肝疾患診断の市場規模、シェア、動向分析レポート：診断技術別、疾患別、最終用途別、地域別、セグメント予測、2024年～2030年

肝疾患診断市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界の肝疾患診断市場規模は、2024年から2030年にかけてCAGR 6.61％で拡大し、2030年には555億8,000万米ドルに達すると予測されています。

市場参入企業による資金調達や研究イニシアチブの増加は、市場成長を促進すると期待される主要要因の1つです。例えば、2019年11月、Glycotest, Inc.は、Shanghai Fosun Pharmaceutical Co., Ltd.（Fosun Pharma）から1,000万米ドルのシリーズA資金調達の2回目の300万米ドルのトランシェを受け取った。この投資により、グリコテスト社は肝細胞がんパネル技術を佛山製薬社に譲渡し、中国での事業化と、現在パイプライン中の肝がんおよび肝線維症の検査を開発します。

各社は医療の質を向上させるため、共同研究や提携に注力しており、これが市場を牽引すると予想されます。例えば、2019年10月、Perspectum DiagnosticsはシンガポールのPrecious Medical CenterでLiverMultiScanを提供するパートナーシップを締結しました。この提携の目的は、健康診断の不可欠な部分として肝臓チェックを考慮するよう人々の意識を喚起することでした。

良性病変と悪性病変を正確に区別できる新しい診断法の開発を支援する研究開発が市場の成長を促進すると予想されます。例えば、ベルリン・シャリテ大学（Charite-Universitatsmedizin Berlin）の研究者は、腫瘍の機械的特性を可視化するためにトモエラストグラフィーを使用し、腫瘍の一貫性の等級付けを検出するための新しい磁気共鳴画像（MRI）技術を開発しました。

さらに、企業は高い感度と特異性を持つ新しい検査を開発するために臨床試験を行っています。例えば、先端医療研究所は、肝硬変患者1,600人を対象に、cfDNAメチル化の定量化による侵襲的生検を行い、超音波検査法と比較する臨床試験を実施しています。この検査は2020年に完了する予定です。

正確な診断法の開発と商業化が市場を押し上げると予想されます。例えば、2020年3月、ENDRA Life Sciences Inc.はTAEUS FLIPシステムのCEマークを取得しました。このシステムは、非アルコール性脂肪性肝疾患（NAFLD）と非アルコール性脂肪性肝炎（NASH）を特定・監視するために肝脂肪を測定します。ポイント・オブ・ケアで肝臓の脂肪を正確に定量化する超音波システムです。

肝疾患診断市場レポートハイライト

• 画像診断分野が最大の収益シェアを占め、CAGRが最も速い成長が見込まれます。これは、肝疾患診断市場の主要企業が先進的な画像診断技術を開発するためのイニシアチブを数多くとっていることが背景にあります。
• 病院セグメントは、2023年に約45.07%の最大の売上シェアを占めました。患者の大多数が診断検査機器を完備した病院を利用しているためです。
• 北米が市場を独占し、2023年には41.71%を超える最大の収益シェアを占め、次いで欧州が続いた。研究開発への高い投資と主要プレイヤーの存在が、同地域の肝疾患診断市場成長の要因として期待されています。
• アジア太平洋地域は予測期間中に最も速いCAGRで成長すると予想されます。高齢者人口の増加と定期検診に対する意識が、この地域における肝疾患診断市場の成長に寄与しています。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 世界の肝疾患診断市場の変数、動向、範囲

• 市場系統の見通し
  • 親市場の見通し
  • 関連/補助的な市場見通し。
• 市場力学
  • 市場牽引要因分析
  • 市場抑制要因分析
  • 市場機会分析
• 世界の肝疾患診断市場分析ツール
  • 業界分析- ポーターのファイブフォース分析
  • PESTEL分析

第4章 世界の肝疾患診断市場：診断技術の推定・動向分析

• セグメントダッシュボード
• 世界の肝疾患診断市場の診断技術変動分析
• 世界の肝疾患診断市場規模と動向分析、診断技術別、2018～2030年
• イメージング
• ラボ検査
• 内視鏡検査
• 生検
• その他

第5章 世界の肝疾患診断市場：疾患の推定・動向分析

• セグメントダッシュボード
• 世界の肝疾患診断市場の疾患変動分析
• 世界の肝疾患診断市場の規模と動向分析、疾患別、2018～2030年
• NAFLD
• NASH
• 線維症
• 肝硬変
• HCC
• その他

第6章 世界の肝疾患診断市場：最終用途の推定・動向分析

• セグメントダッシュボード
• 世界の肝疾患診断市場の最終用途変動分析
• 病院
• 研究所
• その他

第7章 肝疾患診断市場：地域の推定・動向分析

• 地域ダッシュボード
• 市場規模、予測動向分析、2018年から2030年：
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • 英国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • ノルウェー
  • スウェーデン
  • デンマーク
• アジア太平洋
  • 日本
  • 中国
  • インド
  • オーストラリア
  • 韓国
  • タイ
• ラテンアメリカ
  • ブラジル
  • アルゼンチン
• 中東・アフリカ
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート

第8章 競合情勢

• 企業/競合の分類
• 戦略マッピング
• 企業市場シェア分析、2023年
• 主要な認証プロバイダー/スキーム所有者のリスト
• 企業プロファイル/上場企業
  • Abbott
  • F. Hoffmann-La Roche Ltd.
  • Thermo Fisher Scientific Inc.
  • Randox Laboratories Ltd
  • Boston Scientific Corporation
  • Laboratory Corporation of America Holdings
  • Fujifilm Corporation
  • Horiba Medical
  • Siemens Healthcare GmbH
  • Quest Diagnostics

List of Tables

• Table 1. List of Secondary Sources
• Table 2. List of Abbreviation
• Table 3. U.S. Liver Disease Diagnostics market, by diagnosis technique, 2018 - 2030 (USD Million)
• Table 4. U.S. Liver Disease Diagnostics market, by disease, 2018 - 2030 (USD Million)
• Table 5. U.S. Liver Disease Diagnostics market, by end use, 2018 - 2030 (USD Million)
• Table 6. North America Liver Disease Diagnostics market, by region, 2018 - 2030 (USD Million)
• Table 7. North America Liver Disease Diagnostics market, by diagnosis technique, 2018 - 2030 (USD Million)
• Table 8. North America Liver Disease Diagnostics market, by disease, 2018 - 2030 (USD Million)
• Table 9. North America Liver Disease Diagnostics market, by end use, 2018 - 2030 (USD Million)
• Table 10. Canada Liver Disease Diagnostics market, by diagnosis technique, 2018 - 2030 (USD Million)
• Table 11. Canada Liver Disease Diagnostics market, by disease, 2018 - 2030 (USD Million)
• Table 12. Canada Liver Disease Diagnostics market, by end use, 2018 - 2030 (USD Million)
• Table 13. Mexico Liver Disease Diagnostics market, by diagnosis technique, 2018 - 2030 (USD Million)
• Table 14. Mexico Liver Disease Diagnostics market, by disease, 2018 - 2030 (USD Million)
• Table 15. Mexico Liver Disease Diagnostics market, by end use, 2018 - 2030 (USD Million)
• Table 16. Europe Liver Disease Diagnostics market, by region, 2018 - 2030 (USD Million)
• Table 17. Europe Liver Disease Diagnostics market, by diagnosis technique, 2018 - 2030 (USD Million)
• Table 18. Europe Liver Disease Diagnostics market, by disease, 2018 - 2030 (USD Million)
• Table 19. Europe Liver Disease Diagnostics market, by end use, 2018 - 2030 (USD Million)
• Table 20. UK Liver Disease Diagnostics market, by diagnosis technique, 2018 - 2030 (USD Million)
• Table 21. UK Liver Disease Diagnostics market, by disease, 2018 - 2030 (USD Million)
• Table 22. UK Liver Disease Diagnostics market, by end use, 2018 - 2030 (USD Million)
• Table 23. Germany Liver Disease Diagnostics market, by diagnosis technique, 2018 - 2030 (USD Million)
• Table 24. Germany Liver Disease Diagnostics market, by disease, 2018 - 2030 (USD Million)
• Table 25. Germany Liver Disease Diagnostics market, by end use, 2018 - 2030 (USD Million)
• Table 26. France Liver Disease Diagnostics market, by diagnosis technique, 2018 - 2030 (USD Million)
• Table 27. France Liver Disease Diagnostics market, by disease, 2018 - 2030 (USD Million)
• Table 28. France Liver Disease Diagnostics market, by end use, 2018 - 2030 (USD Million)
• Table 29. Italy Liver Disease Diagnostics market, by diagnosis technique, 2018 - 2030 (USD Million)
• Table 30. Italy Liver Disease Diagnostics market, by disease, 2018 - 2030 (USD Million)
• Table 31. Italy Liver Disease Diagnostics market, by end use, 2018 - 2030 (USD Million)
• Table 32. Spain Liver Disease Diagnostics market, by diagnosis technique, 2018 - 2030 (USD Million)
• Table 33. Spain Liver Disease Diagnostics market, by disease, 2018 - 2030 (USD Million)
• Table 34. Spain Liver Disease Diagnostics market, by end use, 2018 - 2030 (USD Million)
• Table 35. Denmark Liver Disease Diagnostics market, by diagnosis technique, 2018 - 2030 (USD Million)
• Table 36. Denmark Liver Disease Diagnostics market, by disease, 2018 - 2030 (USD Million)
• Table 37. Denmark Liver Disease Diagnostics market, by end use, 2018 - 2030 (USD Million)
• Table 38. Sweden Liver Disease Diagnostics market, by diagnosis technique, 2018 - 2030 (USD Million)
• Table 39. Sweden Liver Disease Diagnostics market, by disease, 2018 - 2030 (USD Million)
• Table 40. Sweden Liver Disease Diagnostics market, by end use, 2018 - 2030 (USD Million)
• Table 41. Norway Liver Disease Diagnostics market, by diagnosis technique, 2018 - 2030 (USD Million)
• Table 42. Norway Liver Disease Diagnostics market, by disease, 2018 - 2030 (USD Million)
• Table 43. Norway Liver Disease Diagnostics market, by end use, 2018 - 2030 (USD Million)
• Table 44. Asia Pacific Liver Disease Diagnostics market, by region, 2018 - 2030 (USD Million)
• Table 45. Asia Pacific Liver Disease Diagnostics market, by diagnosis technique, 2018 - 2030 (USD Million)
• Table 46. Asia Pacific Liver Disease Diagnostics market, by disease, 2018 - 2030 (USD Million)
• Table 47. Asia Pacific Liver Disease Diagnostics market, by end use, 2018 - 2030 (USD Million)
• Table 48. Japan Liver Disease Diagnostics market, by diagnosis technique, 2018 - 2030 (USD Million)
• Table 49. Japan Liver Disease Diagnostics market, by disease, 2018 - 2030 (USD Million)
• Table 50. Japan Liver Disease Diagnostics market, by end use, 2018 - 2030 (USD Million)
• Table 51. China Liver Disease Diagnostics market, by diagnosis technique, 2018 - 2030 (USD Million)
• Table 52. China Liver Disease Diagnostics market, by disease, 2018 - 2030 (USD Million)
• Table 53. China Liver Disease Diagnostics market, by end use, 2018 - 2030 (USD Million)
• Table 54. India Liver Disease Diagnostics market, by diagnosis technique, 2018 - 2030 (USD Million)
• Table 55. India Liver Disease Diagnostics market, by disease, 2018 - 2030 (USD Million)
• Table 56. India Liver Disease Diagnostics market, by end use, 2018 - 2030 (USD Million)
• Table 57. Australia Liver Disease Diagnostics market, by diagnosis technique, 2018 - 2030 (USD Million)
• Table 58. Australia Liver Disease Diagnostics market, by disease, 2018 - 2030 (USD Million)
• Table 59. Australia Liver Disease Diagnostics market, by end use, 2018 - 2030 (USD Million)
• Table 60. South Korea Liver Disease Diagnostics market, by diagnosis technique, 2018 - 2030 (USD Million)
• Table 61. South Korea Liver Disease Diagnostics market, by disease, 2018 - 2030 (USD Million)
• Table 62. South Korea Liver Disease Diagnostics market, by end use, 2018 - 2030 (USD Million)
• Table 63. Thailand Liver Disease Diagnostics market, by diagnosis technique, 2018 - 2030 (USD Million)
• Table 64. Thailand Liver Disease Diagnostics market, by disease, 2018 - 2030 (USD Million)
• Table 65. Thailand Liver Disease Diagnostics market, by end use, 2018 - 2030 (USD Million)
• Table 66. Latin America Liver Disease Diagnostics market, by region, 2018 - 2030 (USD Million)
• Table 67. Latin America Liver Disease Diagnostics market, by diagnosis technique, 2018 - 2030 (USD Million)
• Table 68. Latin America Liver Disease Diagnostics market, by disease, 2018 - 2030 (USD Million)
• Table 69. Latin America Liver Disease Diagnostics market, by end use, 2018 - 2030 (USD Million)
• Table 70. Brazil Liver Disease Diagnostics market, by diagnosis technique, 2018 - 2030 (USD Million)
• Table 71. Brazil Liver Disease Diagnostics market, by disease, 2018 - 2030 (USD Million)
• Table 72. Brazil Liver Disease Diagnostics market, by end use, 2018 - 2030 (USD Million)
• Table 73. Argentina Liver Disease Diagnostics market, by diagnosis technique, 2018 - 2030 (USD Million)
• Table 74. Argentina Liver Disease Diagnostics market, by disease, 2018 - 2030 (USD Million)
• Table 75. Argentina Liver Disease Diagnostics market, by end use, 2018 - 2030 (USD Million)
• Table 76. MEA Liver Disease Diagnostics market, by region, 2018 - 2030 (USD Million)
• Table 77. MEA Liver Disease Diagnostics market, by diagnosis technique, 2018 - 2030 (USD Million)
• Table 78. MEA Liver Disease Diagnostics market, by disease, 2018 - 2030 (USD Million)
• Table 79. MEA Liver Disease Diagnostics market, by end use, 2018 - 2030 (USD Million)
• Table 80. South Africa Liver Disease Diagnostics market, by diagnosis technique, 2018 - 2030 (USD Million)
• Table 81. South Africa Liver Disease Diagnostics market, by disease, 2018 - 2030 (USD Million)
• Table 82. South Africa Liver Disease Diagnostics market, by end use, 2018 - 2030 (USD Million)
• Table 83. Saudi Arabia Liver Disease Diagnostics market, by diagnosis technique, 2018 - 2030 (USD Million)
• Table 84. Saudi Arabia Liver Disease Diagnostics market, by disease, 2018 - 2030 (USD Million)
• Table 85. Saudi Arabia Liver Disease Diagnostics market, by end use, 2018 - 2030 (USD Million)
• Table 86. UAE Liver Disease Diagnostics market, by diagnosis technique, 2018 - 2030 (USD Million)
• Table 87. UAE Liver Disease Diagnostics market, by disease, 2018 - 2030 (USD Million)
• Table 88. Kuwait Liver Disease Diagnostics market, by diagnosis technique, 2018 - 2030 (USD Million)
• Table 89. Kuwait Liver Disease Diagnostics market, by disease, 2018 - 2030 (USD Million)
• Table 90. Kuwait Liver Disease Diagnostics market, by end use, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1. Market research process
• Fig. 2. Data triangulation techniques
• Fig. 3. Primary research pattern
• Fig. 4. Market research approaches
• Fig. 5. Value-chain-based sizing & forecasting
• Fig. 6. QFD modelling for market share assessment
• Fig. 7. Market formulation & validation
• Fig. 8. Liver disease diagnostics: Market outlook
• Fig. 9. Liver disease diagnostics: Competitive insights
• Fig. 10. Parent market outlook
• Fig. 11. Related/ancillary market outlook
• Fig. 12. Penetration and growth prospect mapping
• Fig. 13. Industry value chain analysis
• Fig. 14. Liver disease diagnostics market driver impact
• Fig. 15. Liver disease diagnostics market restraint impact
• Fig. 16. Liver disease diagnostics market strategic initiatives analysis
• Fig. 17. Liver disease diagnostics market: disease movement analysis
• Fig. 18. Liver disease diagnostics market: disease outlook and key takeaways
• Fig. 19. NAFLD market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 20. NASH market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 21. Fibrosis market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 22. Cirrhosis market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 23. HCC market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 24. Others market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 25. Liver disease diagnostics market: Diagnosis technique movement analysis
• Fig. 26. Liver disease diagnostics market: Diagnosis technique outlook and key takeaways
• Fig. 27. Imaging market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 28. Laboratory tests market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 29. Endoscopy market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 30. Biopsy market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 31. Others market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 32. Liver disease diagnostics market: End use movement analysis
• Fig. 33. Liver disease diagnostics market: End use outlook and key takeaways
• Fig. 34. Hospitals market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 35. Laboratories market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 36. Others market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 37. Global liver disease diagnostics market: Regional movement analysis
• Fig. 38. Global liver disease diagnostics market: Regional outlook and key takeaways
• Fig. 39. North America market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 40. U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 41. Canada market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 42. Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 43. Europe market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 44. UK market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 45. Germany market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 46. France market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 47. Italy market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 48. Spain market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 49. Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 50. Norway market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 51. Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 52. Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 53. Japan market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 54. China market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 55. India market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 56. Australia market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 57. Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 58. South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 59. Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 60. Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 61. Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 62. Middle East and Africa. market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 63. Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 64. South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 65. UAE market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 66. Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)

Liver Disease Diagnostics Market Growth & Trends:

The global liver disease diagnostics market size is expected to reach USD 55.58 billion by 2030, expanding at a CAGR of 6.61% from 2024 to 2030, according to a new report by Grand View Research, Inc. increasing funding and research initiatives undertaken by market players is one of the major factors expected to propel market growth. For instance, in November 2019, Glycotest, Inc. received the second USD 3.0 million tranche of USD 10.0 million Series A funding from Shanghai Fosun Pharmaceutical Co., Ltd.(Fosun Pharma). Under this investment, Glycotest, Inc. transferred HCC panel technology to Fosun Pharma to commercialize in China and develop tests for liver cancer and liver fibrosis that are currently under pipeline.

Companies are focusing on collaborations and partnership to improve the quality of care,which is anticipated to drive the market. For instance, in October 2019, Perspectum Diagnostics entered into a partnership to offer LiverMultiScan at Precious Medical Center in Singapore. The aim of this partnership was to create awareness among people to consider liver checking as an integral part of their health screening.

Researchers conducting studies to support the development of novel diagnostic methods that can accurately differentiate between benign and malignant lesions are expected to fuel market growth. For instance, researchers from Charite - Universitatsmedizin Berlin used tomoelastography to visualize mechanical properties of tumors and developed a new Magnetic Resonance Imaging (MRI) technique to detect grading of tumor consistency.

Furthermore, companies are conducting clinical trials to develop new tests with high sensitivity and specificity. For instance, Laboratory for Advanced Medicine is conducting a clinical trial on 1,600 patients with liver cirrhosis using invasive biopsy through quantification of cfDNA methylation and comparing it with ultrasound technique. The test is projected to be completed in 2020.

Development and commercialization of accurate diagnostic methods is expected to boost the market. For instance, in March 2020, ENDRA Life Sciences Inc. received CE mark for TAEUS FLIP system. This system measures liver fat to identify and monitor Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH). It is an ultrasound system that accurately and at point of care quantifies fat in the liver.

Liver Disease Diagnostics Market Report Highlights:

• The imaging segment accounted for the largest revenue share and is expected to grow at the fastest CAGR. This is attributed to the rising number of initiatives taken by key players in the liver disease diagnostics market to develop advanced imaging techniques.
• The hospitals segment held the largest revenue share of around 45.07% in 2023 as the majority of patients rely on hospitals well-equipped with diagnostic testing devices.
• North America dominated the market and accounted for the largest revenue share of over 41.71% in 2023 followed by Europe. High investments in R&D and the presence of key players are some factors expected to be responsible for the growth of the market for liver disease diagnostics in the region.
• Asia Pacific is expected to grow at the fastest CAGR during the forecast period. Increasing geriatric population and awareness about regular check-ups are contributing to the growth of the market for liver disease diagnostics in this region.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Market Definitions
  • 1.2.1. Diagnosis Technique Segment
  • 1.2.2. Disease Segment
  • 1.2.3. End Use Segment
• 1.3. Information analysis
  • 1.3.1. Market formulation & data visualization
• 1.4. Data validation & publishing
• 1.5. Information Procurement
  • 1.5.1. Primary Research
• 1.6. Information or Data Analysis
• 1.7. Market Formulation & Validation
• 1.8. Market Model
• 1.9. Total Market: CAGR Calculation
• 1.10. Objectives
  • 1.10.1. Objective 1
  • 1.10.2. Objective 2

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Insights Landscape

Chapter 3. Global Liver Disease Diagnostics Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook.
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Rising Prevalence of Liver Diseases
    • 3.2.1.2. Advancements in Diagnostic Technologies
    • 3.2.1.3. Increasing Awareness and Early Detection
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. High Cost of Advanced Diagnostics
    • 3.2.2.2. Limited Awareness in Developing Regions
  • 3.2.3. Market opportunity analysis
• 3.3. Global Liver Disease Diagnostics Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
  • 3.3.2. PESTEL Analysis

Chapter 4. Global Liver Disease Diagnostics Market: Diagnosis Technique Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Global Liver Disease Diagnostics Market Diagnosis Technique Movement Analysis
• 4.3. Global Liver Disease Diagnostics Market Size & Trend Analysis, by Diagnosis Technique, 2018 to 2030 (USD Million)
• 4.4. Imaging
  • 4.4.1. Imaging market estimates and forecasts 2018 to 2030 (USD Million)
• 4.5. Laboratory Tests
  • 4.5.1. Laboratory Tests market estimates and forecasts 2018 to 2030 (USD Million)
• 4.6. Endoscopy
  • 4.6.1. Endoscopy market estimates and forecasts 2018 to 2030 (USD Million)
• 4.7. Biopsy
  • 4.7.1. Biopsy market estimates and forecasts 2018 to 2030 (USD Million)
• 4.8. Others
  • 4.8.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Global Liver Disease Diagnostics Market: Disease Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Global Liver Disease Diagnostics Market Disease Movement Analysis
• 5.3. Global Liver Disease Diagnostics Market Size & Trend Analysis, by Disease, 2018 to 2030 (USD Million)
• 5.4. NAFLD
  • 5.4.1. NAFLD market estimates and forecasts 2018 to 2030 (USD Million)
• 5.5. NASH
  • 5.5.1. NASH market estimates and forecasts 2018 to 2030 (USD Million)
• 5.6. Fibrosis
  • 5.6.1. Fibrosis market estimates and forecasts 2018 to 2030 (USD Million)
• 5.7. Cirrhosis
  • 5.7.1. Cirrhosis market estimates and forecasts 2018 to 2030 (USD Million)
• 5.8. HCC
  • 5.8.1. HCC market estimates and forecasts 2018 to 2030 (USD Million)
• 5.9. Others
  • 5.9.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Global Liver Disease Diagnostics Market: End Use Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Global Liver Disease Diagnostics Market End Use Movement Analysis
  • 6.2.1. Global Liver Disease Diagnostics Market Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
• 6.3. Hospitals
  • 6.3.1. Hospitals market estimates and forecasts 2018 to 2030 (USD Million)
• 6.4. Laboratories
  • 6.4.1. Laboratories market estimates and forecasts 2018 to 2030 (USD Million)
• 6.5. Others
  • 6.5.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Liver Disease Diagnostics Market: Regional Estimates & Trend Analysis

• 7.1. Regional Dashboard
• 7.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 7.3. North America
  • 7.3.1. U.S.
    • 7.3.1.1. Key country dynamics
    • 7.3.1.2. Regulatory framework/ reimbursement structure
    • 7.3.1.3. Competitive scenario
    • 7.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.3.2. Canada
    • 7.3.2.1. Key country dynamics
    • 7.3.2.2. Regulatory framework/ reimbursement structure
    • 7.3.2.3. Competitive scenario
    • 7.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.3.3. Mexico
    • 7.3.3.1. Key country dynamics
    • 7.3.3.2. Regulatory framework/ reimbursement structure
    • 7.3.3.3. Competitive scenario
    • 7.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
• 7.4. Europe
  • 7.4.1. UK
    • 7.4.1.1. Key country dynamics
    • 7.4.1.2. Regulatory framework/ reimbursement structure
    • 7.4.1.3. Competitive scenario
    • 7.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.2. Germany
    • 7.4.2.1. Key country dynamics
    • 7.4.2.2. Regulatory framework/ reimbursement structure
    • 7.4.2.3. Competitive scenario
    • 7.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.3. France
    • 7.4.3.1. Key country dynamics
    • 7.4.3.2. Regulatory framework/ reimbursement structure
    • 7.4.3.3. Competitive scenario
    • 7.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.4. Italy
    • 7.4.4.1. Key country dynamics
    • 7.4.4.2. Regulatory framework/ reimbursement structure
    • 7.4.4.3. Competitive scenario
    • 7.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.5. Spain
    • 7.4.5.1. Key country dynamics
    • 7.4.5.2. Regulatory framework/ reimbursement structure
    • 7.4.5.3. Competitive scenario
    • 7.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.6. Norway
    • 7.4.6.1. Key country dynamics
    • 7.4.6.2. Regulatory framework/ reimbursement structure
    • 7.4.6.3. Competitive scenario
    • 7.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.7. Sweden
    • 7.4.7.1. Key country dynamics
    • 7.4.7.2. Regulatory framework/ reimbursement structure
    • 7.4.7.3. Competitive scenario
    • 7.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.8. Denmark
    • 7.4.8.1. Key country dynamics
    • 7.4.8.2. Regulatory framework/ reimbursement structure
    • 7.4.8.3. Competitive scenario
    • 7.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 7.5. Asia Pacific
  • 7.5.1. Japan
    • 7.5.1.1. Key country dynamics
    • 7.5.1.2. Regulatory framework/ reimbursement structure
    • 7.5.1.3. Competitive scenario
    • 7.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.2. China
    • 7.5.2.1. Key country dynamics
    • 7.5.2.2. Regulatory framework/ reimbursement structure
    • 7.5.2.3. Competitive scenario
    • 7.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.3. India
    • 7.5.3.1. Key country dynamics
    • 7.5.3.2. Regulatory framework/ reimbursement structure
    • 7.5.3.3. Competitive scenario
    • 7.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.4. Australia
    • 7.5.4.1. Key country dynamics
    • 7.5.4.2. Regulatory framework/ reimbursement structure
    • 7.5.4.3. Competitive scenario
    • 7.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.5. South Korea
    • 7.5.5.1. Key country dynamics
    • 7.5.5.2. Regulatory framework/ reimbursement structure
    • 7.5.5.3. Competitive scenario
    • 7.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.6. Thailand
    • 7.5.6.1. Key country dynamics
    • 7.5.6.2. Regulatory framework/ reimbursement structure
    • 7.5.6.3. Competitive scenario
    • 7.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 7.6. Latin America
  • 7.6.1. Brazil
    • 7.6.1.1. Key country dynamics
    • 7.6.1.2. Regulatory framework/ reimbursement structure
    • 7.6.1.3. Competitive scenario
    • 7.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.2. Argentina
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Regulatory framework/ reimbursement structure
    • 7.6.2.3. Competitive scenario
    • 7.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 7.7. MEA
  • 7.7.1. South Africa
    • 7.7.1.1. Key country dynamics
    • 7.7.1.2. Regulatory framework/ reimbursement structure
    • 7.7.1.3. Competitive scenario
    • 7.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.2. Saudi Arabia
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Regulatory framework/ reimbursement structure
    • 7.7.2.3. Competitive scenario
    • 7.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.3. UAE
    • 7.7.3.1. Key country dynamics
    • 7.7.3.2. Regulatory framework/ reimbursement structure
    • 7.7.3.3. Competitive scenario
    • 7.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.4. Kuwait
    • 7.7.4.1. Key country dynamics
    • 7.7.4.2. Regulatory framework/ reimbursement structure
    • 7.7.4.3. Competitive scenario
    • 7.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Company/Competition Categorization
• 8.2. Strategy Mapping
• 8.3. Company Market Share Analysis, 2023
• 8.4. List of Key Certification Providers/Scheme Owners
• 8.5. Company Profiles/Listing
  • 8.5.1. Abbott
    • 8.5.1.1. Company overview
    • 8.5.1.2. Financial performance
    • 8.5.1.3. Product benchmarking
    • 8.5.1.4. Strategic initiatives
  • 8.5.2. F. Hoffmann-La Roche Ltd.
    • 8.5.2.1. Company overview
    • 8.5.2.2. Financial performance
    • 8.5.2.3. Product benchmarking
    • 8.5.2.4. Strategic initiatives
  • 8.5.3. Thermo Fisher Scientific Inc.
    • 8.5.3.1. Company overview
    • 8.5.3.2. Financial performance
    • 8.5.3.3. Product benchmarking
    • 8.5.3.4. Strategic initiatives
  • 8.5.4. Randox Laboratories Ltd
    • 8.5.4.1. Company overview
    • 8.5.4.2. Financial performance
    • 8.5.4.3. Product benchmarking
    • 8.5.4.4. Strategic initiatives
  • 8.5.5. Boston Scientific Corporation
    • 8.5.5.1. Company overview
    • 8.5.5.2. Financial performance
    • 8.5.5.3. Product benchmarking
    • 8.5.5.4. Strategic initiatives
  • 8.5.6. Laboratory Corporation of America Holdings
    • 8.5.6.1. Company overview
    • 8.5.6.2. Financial performance
    • 8.5.6.3. Product benchmarking
    • 8.5.6.4. Strategic initiatives
  • 8.5.7. Fujifilm Corporation
    • 8.5.7.1. Company overview
    • 8.5.7.2. Financial performance
    • 8.5.7.3. Product benchmarking
    • 8.5.7.4. Strategic initiatives
  • 8.5.8. Horiba Medical
    • 8.5.8.1. Company overview
    • 8.5.8.2. Financial performance
    • 8.5.8.3. Product benchmarking
    • 8.5.8.4. Strategic initiatives
  • 8.5.9. Siemens Healthcare GmbH
    • 8.5.9.1. Company overview
    • 8.5.9.2. Financial performance
    • 8.5.9.3. Product benchmarking
    • 8.5.9.4. Strategic initiatives
  • 8.5.10. Quest Diagnostics
    • 8.5.10.1. Company overview
    • 8.5.10.2. Financial performance
    • 8.5.10.3. Product benchmarking
    • 8.5.10.4. Strategic initiatives